FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2050974857> ?p ?o ?g. }

• W2050974857 endingPage "67" @default.
• W2050974857 startingPage "67" @default.
• W2050974857 abstract "Aromatase inhibitor strategies in metastatic breast cancer Heather L McArthur, Patrick G MorrisBreast Cancer Medicine Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY, USAAbstract: Despite ongoing therapeutic innovations, metastatic breast cancer (MBC) remains a treatable but incurable disease. In the developed world, a diagnosis of MBC without a preceding diagnosis of early stage disease is a rare event. However, approximately one-third of women with early stage breast cancer ultimately experience a distant recurrence. Because the majority of breast cancers express estrogen and/or progesterone receptors and are accordingly considered hormone-sensitive, therapeutic strategies that interfere with hormone-mediated tumorigenesis have been a cornerstone of the breast cancer management paradigm for decades. Historically, the selective estrogen receptor modulator tamoxifen has been the most extensively studied and widely used hormone maneuver in breast cancer. However, a recent therapeutic innovation, namely the successful development of third-generation aromatase inhibitors (AIs), has had a dramatic impact on the treatment paradigm for women with hormone-sensitive MBC. Because of the demonstrated efficacy in postmenopausal breast cancer patients, the generally favorable side-effect profile, and the convenience of oral administration, AIs are now in widespread clinical use. Currently, there are three clinically available third-generation AIs: two reversible, nonsteroidal AIs, letrozole and anastrozole; and one irreversible, steroidal AI, exemestane. All three agents are at least as efficacious as tamoxifen as monotherapy for postmenopausal women with hormone-sensitive MBC. Current clinical research aims to improve upon existing strategies by evaluating AIs in combination with systemic chemotherapy regimens and/or novel targeted agents. It is hoped that these therapeutic innovations will lead to ongoing improvements in quality of life parameters and ideally survival for women with hormone-sensitive MBC.Keywords: metastatic, breast cancer, aromatase inhibitors" @default.
• W2050974857 created "2016-06-24" @default.
• W2050974857 creator A5007002927 @default.
• W2050974857 creator A5067642403 @default.
• W2050974857 date "2009-07-01" @default.
• W2050974857 modified "2023-10-18" @default.
• W2050974857 title "Aromatase inhibitor strategies in metastatic breast cancer" @default.
• W2050974857 cites W1839333839 @default.
• W2050974857 cites W1932574503 @default.
• W2050974857 cites W1993837674 @default.
• W2050974857 cites W1996920020 @default.
• W2050974857 cites W2011894404 @default.
• W2050974857 cites W2022102157 @default.
• W2050974857 cites W2029278810 @default.
• W2050974857 cites W2030091792 @default.
• W2050974857 cites W2030217517 @default.
• W2050974857 cites W2032144589 @default.
• W2050974857 cites W2046222346 @default.
• W2050974857 cites W2067486245 @default.
• W2050974857 cites W2088573877 @default.
• W2050974857 cites W2100375606 @default.
• W2050974857 cites W2102620699 @default.
• W2050974857 cites W2115759102 @default.
• W2050974857 cites W2126275851 @default.
• W2050974857 cites W2132846837 @default.
• W2050974857 cites W2133667885 @default.
• W2050974857 cites W2133764838 @default.
• W2050974857 cites W2136034662 @default.
• W2050974857 cites W2139726760 @default.
• W2050974857 cites W2146384083 @default.
• W2050974857 cites W2149908785 @default.
• W2050974857 cites W2155445734 @default.
• W2050974857 cites W2159459001 @default.
• W2050974857 cites W2166969772 @default.
• W2050974857 cites W2168030291 @default.
• W2050974857 cites W2169073956 @default.
• W2050974857 cites W2171831144 @default.
• W2050974857 cites W2202169216 @default.
• W2050974857 cites W2315688397 @default.
• W2050974857 cites W2315747388 @default.
• W2050974857 cites W2336312508 @default.
• W2050974857 cites W2341534082 @default.
• W2050974857 cites W2508460892 @default.
• W2050974857 cites W269337079 @default.
• W2050974857 doi "https://doi.org/10.2147/ijwh.s4217" @default.
• W2050974857 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/2971713" @default.
• W2050974857 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/21072276" @default.
• W2050974857 hasPublicationYear "2009" @default.
• W2050974857 type Work @default.
• W2050974857 sameAs 2050974857 @default.
• W2050974857 citedByCount "7" @default.
• W2050974857 countsByYear W20509748572012 @default.
• W2050974857 countsByYear W20509748572013 @default.
• W2050974857 countsByYear W20509748572016 @default.
• W2050974857 countsByYear W20509748572017 @default.
• W2050974857 countsByYear W20509748572018 @default.
• W2050974857 crossrefType "journal-article" @default.
• W2050974857 hasAuthorship W2050974857A5007002927 @default.
• W2050974857 hasAuthorship W2050974857A5067642403 @default.
• W2050974857 hasBestOaLocation W20509748571 @default.
• W2050974857 hasConcept C121608353 @default.
• W2050974857 hasConcept C126322002 @default.
• W2050974857 hasConcept C143998085 @default.
• W2050974857 hasConcept C2775860665 @default.
• W2050974857 hasConcept C2775930923 @default.
• W2050974857 hasConcept C2776166826 @default.
• W2050974857 hasConcept C2776215463 @default.
• W2050974857 hasConcept C2777176818 @default.
• W2050974857 hasConcept C2778504769 @default.
• W2050974857 hasConcept C2778812593 @default.
• W2050974857 hasConcept C29456083 @default.
• W2050974857 hasConcept C530470458 @default.
• W2050974857 hasConcept C71924100 @default.
• W2050974857 hasConceptScore W2050974857C121608353 @default.
• W2050974857 hasConceptScore W2050974857C126322002 @default.
• W2050974857 hasConceptScore W2050974857C143998085 @default.
• W2050974857 hasConceptScore W2050974857C2775860665 @default.
• W2050974857 hasConceptScore W2050974857C2775930923 @default.
• W2050974857 hasConceptScore W2050974857C2776166826 @default.
• W2050974857 hasConceptScore W2050974857C2776215463 @default.
• W2050974857 hasConceptScore W2050974857C2777176818 @default.
• W2050974857 hasConceptScore W2050974857C2778504769 @default.
• W2050974857 hasConceptScore W2050974857C2778812593 @default.
• W2050974857 hasConceptScore W2050974857C29456083 @default.
• W2050974857 hasConceptScore W2050974857C530470458 @default.
• W2050974857 hasConceptScore W2050974857C71924100 @default.
• W2050974857 hasLocation W20509748571 @default.
• W2050974857 hasLocation W20509748572 @default.
• W2050974857 hasLocation W20509748573 @default.
• W2050974857 hasLocation W20509748574 @default.
• W2050974857 hasOpenAccess W2050974857 @default.
• W2050974857 hasPrimaryLocation W20509748571 @default.
• W2050974857 hasRelatedWork W1491737910 @default.
• W2050974857 hasRelatedWork W1781289545 @default.
• W2050974857 hasRelatedWork W1966100371 @default.
• W2050974857 hasRelatedWork W1990479899 @default.
• W2050974857 hasRelatedWork W2060548158 @default.
• W2050974857 hasRelatedWork W2067013005 @default.

• next